CareDx, Inc. (NASDAQ:CDNA) major shareholder Neil Gagnon acquired 6,496 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The shares were bought at an average price of $3.05 per share, with a total value of $19,812.80. Following the transaction, the insider now owns 916,546 shares in the company, valued at approximately $2,795,465.30. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Neil Gagnon also recently made the following trade(s):
- On Monday, August 28th, Neil Gagnon acquired 21,448 shares of CareDx stock. The shares were bought at an average price of $2.77 per share, with a total value of $59,410.96.
- On Friday, August 25th, Neil Gagnon acquired 35,119 shares of CareDx stock. The shares were bought at an average price of $2.92 per share, with a total value of $102,547.48.
- On Monday, July 24th, Neil Gagnon acquired 1,486 shares of CareDx stock. The shares were bought at an average price of $1.23 per share, with a total value of $1,827.78.
- On Thursday, June 29th, Neil Gagnon acquired 1,808 shares of CareDx stock. The shares were bought at an average price of $1.11 per share, with a total value of $2,006.88.
- On Friday, June 23rd, Neil Gagnon acquired 63,120 shares of CareDx stock. The shares were bought at an average price of $1.10 per share, with a total value of $69,432.00.
CareDx, Inc. (NASDAQ CDNA) remained flat at $2.98 during mid-day trading on Monday. The stock had a trading volume of 9,752 shares. The firm’s market cap is $67.17 million. CareDx, Inc. has a 1-year low of $0.76 and a 1-year high of $4.66. The stock’s 50 day moving average is $1.96 and its 200-day moving average is $1.49.
CareDx (NASDAQ:CDNA) last announced its earnings results on Thursday, August 10th. The company reported ($0.19) EPS for the quarter, meeting the consensus estimate of ($0.19). CareDx had a negative return on equity of 85.68% and a negative net margin of 61.27%. The business had revenue of $12.05 million during the quarter, compared to the consensus estimate of $11.87 million. On average, equities research analysts predict that CareDx, Inc. will post ($0.82) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Insider Buying: CareDx, Inc. (CDNA) Major Shareholder Purchases $19,812.80 in Stock” was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.themarketsdaily.com/2017/09/11/insider-buying-caredx-inc-cdna-major-shareholder-purchases-19812-80-in-stock.html.
A number of analysts recently commented on the company. Zacks Investment Research upgraded CareDx from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research report on Monday, September 4th. ValuEngine upgraded CareDx from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 24th.
A number of institutional investors have recently made changes to their positions in the stock. Gagnon Securities LLC lifted its stake in CareDx by 2.9% in the 2nd quarter. Gagnon Securities LLC now owns 2,084,292 shares of the company’s stock worth $2,314,000 after acquiring an additional 57,954 shares in the last quarter. Royce & Associates LP lifted its stake in CareDx by 23.5% in the 1st quarter. Royce & Associates LP now owns 526,472 shares of the company’s stock worth $737,000 after acquiring an additional 100,111 shares in the last quarter. Finally, Stonepine Capital Management LLC purchased a new stake in CareDx in the 2nd quarter worth about $212,000. 29.15% of the stock is owned by hedge funds and other institutional investors.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.